Lunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient Cohorts for Pharma Partnerships

About this update from Lunai Bioworks Inc.

Collaboration converts patient-led data into trial-ready cohorts to support drug development, commercial partnerships, and revenue-generating opportunities. Initial programs underway to integrate rare disease datasets and advance commercial partnership opportunities with pharmaceutical companies. SACRAMENTO, Calif., and HOUSTON, April 15, 2026 /PRNewswire/ -- Lunai Bioworks, Inc. (NASDAQ: LNAI) ("Lunai"), an AI-driven drug discovery company, and Geneial, Inc., a precision medicine data infrastructure and patient engagement company, today announced that BioSymetrics, a wholly owned Lunai subsidiary, has signed a Letter of Intent (LOI) with Geneial to pursue a strategic collaboration in rare neurological disorders. The collaboration is designed to support rare disease research and advocacy groups in converting fragmented, patient-generated data into actionable drug development programs, including the creation and activation of trial-ready patient cohorts that can support pharmaceutical partnerships. Rare diseases affect approximately 300 million people globally, yet drug development remains constrained by limited access to structured, usable patient data. The targeted rare neurological segment represents a multi-billion-dollar and growing market opportunity. Initial programs are expected to integrate datasets across multiple patient registries, incorporating longitudinal clinical data to support cohort development and translational research across indications. Under the proposed collaboration, BioSymetrics and Geneial plan to: This approach is intended to reduce development risk, improve the probability of trial success, and accelerate timelines by addressing a key bottleneck in rare disease drug development: connecting longitudinal patient data and engaged cohorts with translational research and clinical development opportunities. The companies expect to pursue commercial partnerships enabled by these efforts, supporting potential revenue-generating collaborations and downstream partnering opportunities with pharmaceutical and biotechnology partners. "Geneial's mission is to accelerate precision medicine by connecting patient communities, researchers, and industry partners," said Adam Hansen, CEO of Geneial. "This collaboration connects our AI-enabled patient engagement and data platform with BioSymetrics' capabilities...

View stock analysis, news, and events for Lunai Bioworks Inc.